Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 67.34% is 121% above its 5-year average of -316.79%, near the high end of its 5-year range (-1373.37%–100.00%).
156.60% above its 12-month average of -118.98%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 100.00%.
GROSS MARGIN
67.34%
GROSS MARGIN AVG TTM
-118.98%
GROSS MARGIN AVG 3Y
-285.86%
GROSS MARGIN AVG 5Y
-316.79%
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+156.60%
CURRENT VS 3Y AVG
+123.56%
CURRENT VS 5Y AVG
+121.26%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
42.91%
median of 588 covered companies
CURRENT VS SECTOR MEDIAN
+56.93%
vs the sector median at left
Caribou Biosciences, Inc.
Market Cap
$116.54M
Gross Margin
67.34%
TTM Avg
-118.98%
3Y Avg
-285.86%
5Y Avg
-316.79%
Market Cap
$116.57M
Gross Margin
11.17%
TTM Avg
22.02%
3Y Avg
17.41%
5Y Avg
13.61%
Market Cap
$116.83M
Gross Margin
90.14%
TTM Avg
48.16%
3Y Avg
49.08%
5Y Avg
32.72%
Market Cap
$114.79M
Gross Margin
-7075.00%
TTM Avg
-9131.25%
3Y Avg
-4667.52%
5Y Avg
-3111.68%
Market Cap
$120.24M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$112.52M
Gross Margin
-60.26%
TTM Avg
-75.23%
3Y Avg
-314.56%
5Y Avg
-212.54%
Market Cap
$112.36M
Gross Margin
99.91%
TTM Avg
-67.10%
3Y Avg
-31.47%
5Y Avg
-20.98%
Market Cap
$121.25M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Caribou Biosciences, Inc. (CRBU) | $116.54M | 67.34% | -118.98% | -285.86% | -316.79% |
| Insight Molecular Diagnostics Inc. (IMDX)vs › | $116.57M | 11.17% | 22.02% | 17.41% | 13.61% |
| LENZ Therapeutics, Inc. (LENZ)vs › | $116.83M | 90.14% | 48.16% | 49.08% | 32.72% |
| Genelux Corporation (GNLX)vs › | $114.79M | -7075.00% | -9131.25% | -4667.52% | -3111.68% |
| MaxCyte, Inc. (MXCT)vs › | $114.62M | 79.43% | 81.39% | 84.94% | 86.41% |
| TuHURA Biosciences, Inc. (HURA)vs › | $120.24M | 0.00% | 0.00% | 0.00% | 0.00% |
| Lucid Diagnostics Inc. (LUCD)vs › | $112.52M | -60.26% | -75.23% | -314.56% | -212.54% |
| Coya Therapeutics, Inc. (COYA)vs › | $112.36M | 99.91% | -67.10% | -31.47% | -20.98% |
| enGene Holdings Inc. (ENGN)vs › | $121.25M | 0.00% | 0.00% | 0.00% | 0.00% |
| Cumberland Pharmaceuticals Inc. (CPIX)vs › | $110.73M | 83.37% | 83.81% | 82.64% | 80.50% |
Gross Margin
67.3%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 100.00% |
| 2026-03-31 | 72.92% |
| 2025-12-31 | 100.00% |
| 2025-09-30 | -919.15% |
| 2025-06-30 | 51.33% |
| 2025-03-31 | 25.92% |
| 2024-12-31 | -1337.84% |
| 2024-09-30 | -1373.37% |
| 2024-06-30 | 75.29% |
| 2024-03-31 | 70.77% |
| 2023-12-31 | 44.52% |
| 2023-09-30 | -20.80% |
| 2023-06-30 | -605.81% |
| 2023-03-31 | -634.12% |
| 2022-12-31 | -597.07% |
| 2022-09-30 | 100.00% |
| 2022-06-30 | -438.62% |
| 2022-03-31 | -422.67% |
| 2021-12-31 | 89.33% |
| 2021-09-30 | -298.11% |
| 2021-06-30 | -735.16% |
| 2021-03-31 | -540.92% |
| 2020-12-31 | -1121.95% |
| 2020-09-30 | 100.00% |
| 2020-06-30 | 100.00% |
| 2020-03-31 | 100.00% |
